Breast cancer is the most common solid tumor and the second most common cause of death in women. Despite a large body of literature and progress in breast cancer research, many molecular aspects of this complex disease are still poorly understood, hindering the design of specific and effective therapeutic strategies. To identify the molecules important in breast cancer progression and metastasis, we tested the in vivo effects of inhibiting the functions of various kinases and genes involved in the regulation/modulation of the cytoskeleton by downregulating them in mouse PyMT mammary tumor cells and human breast cancer cell lines. These kinases and cytoskeletal regulators were selected based on their prognostic values for breast cancer patient survival. PyMT tumor cells, in which a selected gene was stably knocked down were injected into the tail veins of mice, and the formation of tumors in the lungs was monitored. One of the several genes found to be important for tumor growth in the lungs was NIMA-related kinases 2 (Nek2), a cell cycle-related protein kinase. Furthermore, Nek2 was also important for tumor growth in the mammary fat pad. In various human breast cancer cell lines, Nek2 knockdown induced aneuploidy and cell cycle arrest that led to cell death. Significantly, the breast cancer cell line most sensitive to Nek2 depletion was of the triple negative breast cancer subtype. Our data indicate that Nek2 has a pivotal role in breast cancer growth at primary and secondary sites, and thus may be an attractive and novel therapeutic target for this disease.
INTRODUCTION
Breast cancer is the most common female malignancy in North America and the second most common cause of cancer death in women. 1 Breast tumors are classified into specific subtypes based on cellular morphology and the presence/absence of the estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 (ERBB2/HER2). Examinations of each subtype's pathophysiology have generated targeted therapies that have extended the survival of some patients with metastatic breast cancers. Such therapies, which include taxanes, aromatase inhibitors and trastuzumab 2, 3 have significantly improved the outcomes for patients with breast cancers of the luminal or HER2 subtypes. Sadly, an effective targeted treatment is still lacking for patients whose tumors are of the highly aggressive triple negative breast cancer (TNBC) subtype. 4, 5 Because kinases are crucial for cancer cell survival, mitosis, migration and invasion, much research has been focused on developing inhibitors against them. [6] [7] [8] Rapidly proliferating tumors like TNBCs rely on tight temporal regulation of the cell cycle and centrosome duplication. Inhibition of the kinases associated with mitosis induces severe defects in centrosome duplication and chromosome segregation that ultimately lead to aneuploidy and cell death. [9] [10] [11] [12] The future of TNBC management may therefore lie in the identification of new cell cycle regulators that control breast cancer progression and metastasis.
The NIMA-related kinases (Nek) proteins belong to a family of serine/threonine kinases named after the NIMA (never in mitosis A) gene originally cloned in Aspergillus nidulans. 13 In mammals, there are 11 family members (Nek1-Nek11) but only four of these proteins, Nek2, Nek6, Nek7 and Nek9, have roles in mitotic progression. 14 Of particular interest is Nek2, which localizes to the centrosome/centriole and helps to establish a bipolar spindle by initiating the separation of centrosomes. [15] [16] [17] High levels of NEK2 protein have been previously described in breast cancers, 18 and Nek2 mRNA overexpression has been reported in different breast cancer subtypes. 19, 20 These observations, coupled with Nek2's function as a major centrosome regulator, marks this kinase as an emerging target of drug discovery interest. [21] [22] [23] In this study, we show that cancer cells lacking Nek2 exhibit aberrant mitosis leading to apoptosis. Furthermore, Nek2 knockdown in cancer cells induces aneuploidy, cell cycle arrest and caspase-dependent and -independent cell death. Mechanistically, Nek2 depletion promotes the activity of the tumor suppressor retinoblastoma protein (pRb) while simultaneously reducing the activation of the cell division regulator histone H3. In vivo, mouse and human cancer cells lacking Nek2 expression grow more slowly than control cells, and give rise to reduced tumor burden in the lungs. Our results suggest that Nek2 inhibition could help to disrupt the cell cycle of TNBC cells, enhancing the effects of current chemotherapeutic interventions.
RESULTS

High Nek2 expression correlates with poor prognosis in breast cancer patients
To identify specific kinases and cytoskeletal regulators important for breast cancer cell survival in vivo, we used stable expression of short-hairpin RNA (shRNA) to silence genes encoding selected cytoskeletal regulators and kinases in mouse PyMT mammary tumors (PyMT cells, previously described in). 24 We selected candidates whose high expression correlated positively with greater risk of patient mortality as evaluated in a cohort of 2312 breast cancer patients (Figure 1a) . By choosing a cutoff of 1.2 for the hazard ratio, we compiled a list of 14 target genes suitable for further study in vivo. We silenced each gene individually in PyMT cells (Supplementary Figure S1a) , and intravenously injected the modified cells into syngeneic recipient mice. The recipients have been monitored to assess whether the lack of each target gene is able to suppress tumor growth in the lung (Supplementary Figure  S1b) . On the basis of our in vivo results and the pharmacological tractability of our 14 genes (as determined by consulting sources such as ChEmbl, PubChem, Drugbank and Sophic Druggable Genome), we chose Nek2 for further indepth investigation. We first confirmed that Nek2 mRNA is overexpressed in basal-like as well as non-basal-like breast cancers in comparison with normal breast tissue (Figure 1b) , and showed that Nek2 overexpression correlates positively with a greater risk of patient mortality (Figure 1c) . We also demonstrated that Nek2 overexpression correlates positively with disease recurrence (Figure 1d ) 25 in breast cancer patients. In order to examine Nek2 protein expression in breast cancer, we performed immunohistological analysis on a tissue microarray comprising of normal and malignant breast tissue from a cohort of 39 patients with TNBC (Supplementary Table S1 ). Invasive ductal carcinomas showed a markedly increased number of cells expressing nuclear Nek2 in comparison with normal breast tissue (Figures 1e and f) . Notably, about 45% of all normal breast tissue showed zero nuclear Nek2 expression intensity, whereas only about 5% of invasive ductal carcinoma were considered to have no expression. Conversely, about 36% of all invasive ductal carcinomas showed strong nuclear Nek2 expression in comparison to about 3% of normal breast tissue samples (Figure 1g ). These results affirm the relevance of evaluating Nek2 as a potential target in human breast cancer.
Nek2 promotes the growth of PyMT cells in the lung
To study the role of Nek2 in tumor growth, we stably knocked down Nek2 in luciferase-expressing PyMT cells using specific shRNA (PyMT-shNek2) (Figures 2a and b) . We then injected PyMTshNek2 or PyMT-ctr cells (expressing scramble shRNA) into female syngeneic mice via the tail vein, and performed live animal imaging to monitor tumor growth in the lungs. At 4 weeks postinjection, tumor cell engraftment was readily detected in all mice injected with PyMT-ctr cells but rarely in mice injected with Figure 1 . Target selection for in vivo tumor growth study and characterization of Nek2 in human breast cancers. (a) Selected human genes associated with poor breast cancer patient prognosis. The Entrez Gene ID and Gene Symbol are indicated, as well as each target's hazard ratio (HR) related to overall patient survival, the Pvalue and the number (n) of breast cancer patients analyzed for that target. (b) Relative Nek2 mRNA expression (density) in normal breast tissue, basal-like or non-basal-like breast cancer tissues, extrapolated from the Richardson data set. 19 (c) Survival curve for a cohort of 2312 breast cancer patients stratified based on high or low Nek2 expression in the patient's tumor. The HR and P-values for the correlation between Nek2 level and patient prognosis are indicated. (d) Relapse-free survival curves (RFS) of patients bearing breast cancers of the basal, luminal A or luminal B subtypes, stratified based on high or low Nek2 expression in the patient's tumor. 25 The HR and P-values for the correlation between Nek2 level and patient prognosis are indicated. PyMT-shNek2 cells (Figure 2c) . Moreover, while all control mice died by 20 weeks postinjection, 50% of mice injected with PyMTshNek2 cells survived past that timepoint, and 20% of these mice were still alive at 50 weeks postinjection (Figure 2d ). Because of Nek2's known role in mitotic progression, 17 we analyzed the cell cycle in PyMT-shNek2 and control cells after serum starvation or nocodazole treatment. Nek2 knockdown increased the G1 population and modestly enhanced the G2/M population, indicating that cell cycle arrest had occurred ( Figures  2e and f) . However, the most interesting effect of Nek2 silencing was the eventual generation of an aneuploid cell population. This aneuploid subset comprised 64% of all PyMT-shNek2 cells at 48 h after serum replenishment, but was virtually absent (0.3% at 48 h) in control cells (Figures 2e and g ). A similar trend was observed following the release from nocodazole treatment (Supplementary Figure S2) . We hypothesized that this induction of aneuploidy upon Nek2 knockdown could underlie the observed increase in G1 cells, and might explain the significant reduction in tumor growth in mice bearing PyMT-shNek2 cells.
Nek2 promotes the growth of human breast cancer cells in vivo To determine whether Nek2 is also important for the cell cycle in human breast cancer cells, we transduced luciferase-expressing MDA-MB-231 cells (TNBC cell line) with either scramble shRNA (MDA-MB-231-ctr) or Nek2 shRNA (MDA-MB-231-shNek2) (Figures  3a and b) . A previous study showed that the in vivo growth of MCF7 or MDA-MB-231 human breast cancer cells could be inhibited by injecting small interfering RNA against Nek2 directly into tumors. 26 We injected MDA-MB-231-shNek2 or control cells into either the tail veins of non-obese diabetic-severe combined immunodeficiency (NOD-SCID) mice or into the fat pads of female NIH-III mice. In NOD-SCID mice, even at 3 weeks postinjection, we detected more tumor cells in the lungs of the animals injected with control cells than in the lungs of those injected with MDA-MB-231-shNek2 cells (Figure 3c Figure S4) . Interestingly, the responses of different human breast cancer cells to Nek2 knockdown were not uniform. HCC1806-shNek2 cultures showed an abnormally high percentage of cells in the G2/M and subG1 phases but no aneuploidy (Supplementary Figure S5 ). In contrast, both an aneuploid cell population and an expanded subG1 population were detected in T47D-shNek2 cells (Supplementary Figure S6) . MCF7-shNek2 cells displayed a decreased proliferation rate compared with controls, in line with their slight increase in G2/M phase (Supplementary Figure S7) . These results emphasize the heterogeneity of human breast cancers but also suggest that the inhibition of Nek2 can interfere with the growth of different breast cancer subtypes.
The reduced tumor burden observed in the lungs of mice injected with MDA-MB-231-shNek2 cells (refer to Figure 3f ) could also result from defects in cell migration or invasion. We therefore evaluated these capacities in MDA-MB-231-shNek2 cells using real-time and transwell migration and invasion assays. MDA-MB-231-shNek2 cells showed slightly decreased migration ability compared with control cells, but no difference in invasion capacity (Supplementary Figure S8) . These data imply that the reduced growth of Nek2-depleted cells in the lungs is mainly due to cell cycle abnormalities, aneuploidy and cell death, with little or no contribution by a defect in either migration or invasion.
To confirm the appearance of aberrant multicentrosomal and multinuclear cells in MDA-MB-231-shNek2 cultures, we stained the cells with antibodies recognizing a-tubulin, pericentrin or centrin2 to visualize microtubules, centrosomes and centrioles, respectively. Although most control cells displayed two centrosomes and normal mitotic spindles, many MDA-MB-231-shNek2 cells showed multiple centrosomes and aberrant mitotic spindles (Figure 5a ). An increase in centrosome numbers in the absence of Nek2 was confirmed by the quantitation of the number of centrioles per pole (Figure 5b ). We then evaluated the percentage of cells undergoing monopolar, bipolar or multipolar division in control and MDA-MB-231-shNek2 cultures. Nek2 knockdown cultures showed a significantly lower percentage of cells with bipolar division, and consequently a higher percentage of cells with multipolar division compared with controls ( Figure 5c ). Furthermore, karyotype analysis confirmed a markedly greater number of chromosomes per cell in MDA-MB-231-shNek2 cultures compared with controls (Figures 5d and e) .
To determine the fate of cells lacking Nek2, we used real-time microscopy and MDA-MB-231 cells engineered to both 1 coexpress doxycycline (DOX)-induced shNek2 and red fluorescent protein, and 2 express green fluorescent protein-conjugated histone 2B (H2B-green fluorescent protein; to label chromosomes). In the absence of DOX (wild-type Nek2 expression), the majority of H2B-green fluorescent protein-expressing MDA-MB-231 cells divided normally into two daughter cells (Figure 5f and Supplementary (Figure 6a, left) . Application of zVAD also decreased the subG1 population among MDA-MB-231-shNek2 cells by 20%, but had no effect on the subG1 population in the control (Figure 6a, right) . Increased apoptosis in the absence of Nek2 was also confirmed by immunohistochemical analysis of CC-3 in tumors isolated from xenografted NIH-III mice. More CC-3 þ cells were observed in tumors from animals xenografted (Figure 6b) . At the molecular level, MDA-MB-231-shNek2 cells revealed reduced phosphorylated pRb and phosphorylated histone H3-Ser10 compared with controls ( Figure 6c ). This result is in line with previous observations that hypophosphorylated pRb functions as a tumor suppressor by inhibiting cell cycle progression, and that phosphorylated histone H3-Ser10 is required for normal chromosome segregation. 27, 28 The fact that abnormalities in these vital cell cycle factors are observed when Nek2 is depleted, further substantiates our contention that Nek2 is required for proper cell cycle progression and chromosome segregation.
DISCUSSION
Over the past few decades, huge efforts have been undertaken to identify new key players in breast cancer progression and metastasis. It is well known that tumor cells act completely differently in culture than they do in vivo, where they are surrounded by stromal cells, and interact with cells of the immune system. These considerations led us to use living animals to test a selection of putative therapeutic targets relevant to breast cancer. We have identified several kinases and cytoskeletal regulators that, when knocked down, reduce or completely inhibit tumor growth in vivo. The particular target examined in this study was 
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Nek2, which is overexpressed in cases of all subtypes of breast cancer. Such overexpression is likely due to amplification of chromosomal region 1q32, which contains the human Nek2 locus. 29 In our study, we have confirmed that Nek2 overexpression correlates positively with higher risks of disease recurrence and mortality in breast cancer patients. We have also shown that Nek2-depleted human breast cancer cells grow poorly in the lungs and mammary fat pads of xenografted mouse recipients. Others have previously reported that Nek2 has a pivotal role in tumor cell growth, 26, 30 we propose that the main effects of Nek2 depletion are a block in cell cycle progression and interference with chromosomal segregation, leading to aneuploidy and subsequent cell death.
We observed that human breast cancer cells lacking Nek2 proliferated less than control cells, and displayed a higher percentage of cells in the G2/M phase. Moreover, cultures of mouse PyMT cells and human TNBC cells both showed a huge population of aneuploid cells and a parallel increase in the subG1 population. Aneuploidy and chromosome instability are common abnormalities in human cancers and are linked to poor clinical outcome. 31 Loss of control over mitotic progression, spindle formation and cytokinesis are all likely to contribute to these abnormalities. However, aneuploidy and aberrant mitosis can also precipitate chromosomal breakage or interchromosomal concatenation, resulting in a lethal genetic imbalance that leads to cell death. Thus, aneuploidy can be a promoter or suppressor for mutations that inhibit tumor cell growth or induce cell death. 32 Our data show that Nek2 knockdown cells display aberrant mitotic figures with multipolar divisions and extra centrosomes. Nek2 is known to phosphorylate mitotic checkpoint proteins such as Mad2 and Cdc20, 33 and to interact with the spindle assembly checkpoint protein Mad1. 34, 35 Nek2 also contributes to the microtubule reorganization necessary for the G2/M transition by phosphorylating several centrosomal substrates, including c-Nap1, rootletin, protein phosphatase 1, ninein-like protein, centrobin and high mobility group AT-hook 2. 36, 37 In accordance with these observations, we could demonstrate that multinuclear cells that lack Nek2 died during mitosis. We also found a higher percentage of CC-3 þ cells in the tumors of mice injected with Nek2 knockdown cells compared with tumors of mice injected with control cells. Taken together, these data suggest that the aneuploidy associated with Nek2 depletion can induce cancer cell death.
Phosphorylation of histone H3-Ser10 is required for normal chromosome condensation and segregation. Our study has shown that Nek2 depletion greatly reduces histone H3-Ser10 phosphorylation. In vitro, Nek2 can phosphorylate histone H3 either directly or through extracellular-regulated kinase 1/p90Rsk2, but it remains under debate whether Nek2 can phosphorylate histone H3 in vivo. 17, 38, 39 In addition, although a direct link between Nek2 and pRb regulation has yet to be reported, we have demonstrated that Nek2 depletion decreases the level of pRb phosphorylation. This reduction could allow more pRb molecules to remain active, and inhibit cell cycle progression. Alternatively, Nek2 and pRb signaling could be interconnected through the mitotic kinetochore protein highly expressed in cancer protein 1 (Hec1). Previous work has shown that Nek2 may participate in chromosome condensation through its interactions with Hec1, 34 and Nek2-dependent phosphorylaton of Hec1 is essential for kinetochore attachments to microtubules during mitosis. 40 Hec1 is functionally linked to the pRb pathway because disruption of pRb activity leads to Hec1 overexpression, inducing defects in chromosome segregation and mitosis. 41 Collectively, these data suggest that Nek2 may be involved in regulating both the histone H3 and pRb pathways.
Interference with mitosis is a well-recognized modality of anticancer therapy. The chemotherapeutic drug Taxol triggers cell death by inactivating the spindle checkpoint, thus inducing aneuploidy and aberrant mitosis. 42 Kinase inhibitors that have the same effects on tumor cells might therefore be helpful adjuncts when used in combination with chemotherapeutic drugs based on other strategies. Viridin analogs, which are highly specific inhibitors of Nek2, can induce centrosome disruption, and inhibit cancer cell growth in vitro. 43 Other recent work has indicated that Nek2 silencing can induce apoptosis of cells that show chromosomal instability, but not of cells with a normal karyotype. 44, 45 Our study provides in vivo validation of the concept that Nek2 is important for tumor growth in both primary and secondary sites, and strengthens the rationale underlying the growing efforts to develop specific therapeutic inhibitors against this kinase.
MATERIALS AND METHODS
Cell lines and plasmids
PyMT mammary tumor cells were derived from mouse mammary tumor virus (MMTV)-PyMT mice and maintained as previously reported. 24 All human breast cancer cell lines (MDA-MB-231, HCC1806, T47D and MCF7) were obtained from the American Type Culture Collection. Unless otherwise indicated, all cell lines were maintained in complete medium (CM), which was Dulbecco's modified Eagle medium supplemented with 10% fetal bovine serum. For serum starvation, cells were cultured overnight in serum-free Dulbecco's modified Eagle medium. For nocodazole treatment, cells were cultured overnight in CM containing 100 ng/ml nocodazole (Sigma). For stable knockdown, control scramble shRNA and gene-specific shRNAs were purchased for lentiviral expression: pLKO.1 for mouse PyMT cells, and pGIPZ/pTRIPZ for human breast cancer cells (Sigma, Oakville, ON, Canada; Open Biosystems, Pittsburgh, PA, USA).
Microarray analysis
(i) Data sets used. We developed a database comprising of 15 publicly available mRNA expression data sets (PMIDs: 16273092, 17545524, 16141321, 16280042, 16478745, 18498629, 17157792, 19421193, 20098429, 20064235, 20490655, 20697068, 18821012, 18593943 and 15721472) . Raw data were preprocessed using the RMA algorithm (PMID: 12582260) with Entrez Gene annotation (PMID: 16284200). Preprocessing was performed in the R statistical environment (v2.11.1) using the affy package of BioConductor (v1.26.1) and v12.1.0 of the updated Entrez Gene annotation packages.
(ii) Ortholog mapping. Human genes were mapped to their mouse orthologs using the Homologene database (build 64) and custom perl scripts.
(iii) Statistical analysis and data visualization. Signal intensities of each candidate gene were median-dichotomized in each data set, as outlined previously (PMID: 20696928), in the R statistical environment (v2.12.1). Survival rates of patients in the 'good' and 'poor' outcome groups were compared using unadjusted Cox proportional hazards modeling, as implemented in the survival package (v2. . Gene association with patient prognosis: the Wald test was used to determine whether the hazard ratio was statistically different from unity. Kaplan-Meier curves were created using the lattice (v0. and latticeExtra (v0.6-15) packages.
Quantitative real-time PCR TRIzol reagent (Invitrogen, Burlington, ON, Canada) was used for total RNA extraction and the iScript reverse transcription kit (BioRad, Mississauga, ON, Canada) was used to produce complementary DNA. Quantitative reverse transcription-PCR reactions were performed in triplicate using SYBR Green mix (Applied Biosystems) and an Applied Biosystems Real-time PCR-7900HT instrument. The amplification of the gapdh/GAPDH gene was used as an internal reference control.
Cell proliferation
Cells were cultured for up to 6 days in CM. Cells were stained with trypan blue and analyzed using a Vi-Cell XR instrument (Beckman Coulter, Mississauga, ON, Canada) to determine viability and establish growth curves. For real-time cell proliferation, cells were subjected to serum starvation or nocodazole treatment as described above, cultured in CM for an additional 5 days, and monitored using an xCELLigence RTCA DP device (Roche Diagnostics, Laval, QC, Canada). The proliferation rate was expressed as the slope (1/h), where a higher slope represents faster cell growth. Cell proliferation was also analyzed by BrdU incorporation and flow cytometry. Briefly, serum-starved or nocodozole-treated cells were cultured overnight in CM containing BrdU starting at 24 or 72 h after CM replenishment. BrdU incorporation was detected using the APC-BrdU kit (BD Biosciences, Mississauga, ON, Canada) following the manufacturer's instructions.
Migration and invasion assays
Transwell filters coated with collagen-I or Matrigel (BD Biosciences, 8 mm pore size) were used for migration or invasion assays, respectively. Cells (2.5 Â 10 4 for migration assays or 5 Â 10 4 for invasion assays) were seeded into the upper chamber in Dulbecco's modified Eagle medium with 0.5% fetal bovine serum. The bottom chamber contained Dulbecco's modified Eagle medium with 20% fetal bovine serum. Cells were allowed to migrate/ invade at 37 1C in 5% CO 2 for 20 h before they were fixed and stained in methanol/methylene blue solution. Cell counts were performed on 10 fields per filter, and the mean was normalized to the migration/invasion cell count of control cells. Real-time cell migration was evaluated using the xCELLigence RTCA DP device (Roche Diagnostics). For this purpose, 1 Â 10 4 , 2 Â 10 4 or 4 Â 10 4 MDA-MB-231 cells per well were seeded in CIMPlates 16 (Roche Diagnostics). The migration rate was expressed as the slope (1/h), where a higher slope represents faster cell movement.
Cell cycle analysis Cells (2 Â 10 5 ) were cultured overnight in serum-free medium or in CM containing nocodazole (100 ng/ml). The medium was changed to CM and the cells were cultured for 24, 48, 72, 96 or 120 h. After ethanol fixation, cells were washed with phosphate-buffered saline, suspended in phosphate-buffered saline containing 2 mg/ml propidium iodide (Sigma) plus 20 mg/ml RNAse (Invitrogen), and examined using a FACSCalibur instrument and ModFit software (BD Biosciences). To evaluate CC-3 þ cells by flow cytometry, the PE Active Caspase-3 Apoptosis Kit (BD Biosciences) was used following the manufacturer's instructions. Cells were acquired and analyzed with CellQuest software (BD Biosciences). For caspase inhibitor studies, cells were cultured in CM containing 50 mM zVAD (Sigma) for 48 h before cell cycle analysis as described above. CC-3 þ cells without zVAD were evaluated in a parallel set of plates as a control.
In vivo analyses of tumor growth 
Karyotyping
Cells were cultured in CM containing nocodazole (100 ng/ml) for 5 h before the treatment with hypotonic solution (0.56% KCl) and fixation in methanol/acetic acid (3:1). Metaphase chromosome spreads were prepared on glass microscope slides, stained with Giemsa solution (Sigma) and counted/analyzed using an upright Leica DM2500 light microscope (Leica Microsystems, Concord, ON, Canada) equipped with a 40x air lens.
Immunofluorescence and real-time microscopy ) were seeded in Nunc eight well chamber slides (Thermo Scientific, Rochester, NY, USA) and cultured overnight in serum-free medium or CM containing nocodazole (100 ng/ml). The medium was changed to CM and cells were cultured for a further 48 h before paraformaldehyde fixation, Triton X-100 permeabilization and blocking in goat serum containing bovine serum albumin. Slides were then incubated with primary anti-a-tubulin (Sigma-Aldrich), antipericentrin (Abcam, Toronto, ON, Canada) or anti-centrin2 (Santa Cruz, Biotechnology, Santa Cruz, CA, USA) antibodies, followed by speciesspecific fluorescent secondary antibodies (Molecular Probes, , Burlington, ON, Canada). DNA was detected with 1.5 mg/ml 4,6-diamidino-2-phenylindole (VECTASHIELD Mounting Medium with DAPI; Vector Laboratories, Nek2 prevents aneuploidy in breast cancer cells P Cappello et al Burlington, ON, Canada). Fluorescent images were obtained and processed using an Olympus-Fluoview-FV1000 confocal microscope, (Olympus, Richmond Hill, ON, Canada). For real-time microscopy, MDA-MB-231 cells coexpressing DOX-inducible red fluorescent protein and shNek2 were transfected with pBOS human histone 2B-green fluorescent protein plasmid using Lipofectamine2000 (Invitrogen). Transfected cells (1 Â 10 4 ) were seeded in eight well chamber slides and cultured overnight as above. The medium was changed to CM with or without DOX (500 ng/ml), and cells were cultured and recorded for an additional 150 h at 37 1C in 5% CO 2 . The CM with or without DOX was replaced every 48 h. Cells were recorded using a Leica DMI 6000B instrument and image analysis was performed using Volocity software (PerkinElmer, Woodbridge, ON, Canada).
Immunohistochemistry
Tissues were fixed in 10% buffered formalin and embedded in paraffin. Tissue sections (5 mm) were stained with hematoxylin and eosin or subjected to immunohistochemical staining to detect CC-3. Briefly, tissue sections were incubated first with anti-CC-3 antibody (1:250; Cell Signaling, Whitby, ON, Canada), then with biotinylated goat anti-rabbit secondary antibody (1:100, Vector Labs) and exposed to ABC reagent (1:200 final A and B dilution; PK-6100, Vector Labs). The DAB substrate kit (SK-4100, Vector Labs) was used to visualize anti-CC-3 antibody staining. Imaging was performed on a Leica DM2500 microscope.
The tissue microarray contains 39 TNBCs from our institution. For each case there were two 0.6 mm biopsy-cores of invasive carcinoma and one of normal breast tissue taken. All cores were taken from routinely processed clinical blocks. Formalin-fixed paraffin-embedded tissues had been fixed in formalin between 16 and 80 h before processing and embedding. Estrogen receptor, progesterone receptor and initial human epidermal receptor 2 (HER2) assessment was performed immunohistochemically in accordance with current clinical guidelines. Equivocal HER2 cases were also tested by fluorescence in situ hybridization. The Nek2 antibody was optimized on malignant and normal breast tissues. The tissue microarray was microwaved, exposed to Tris-EDTA pH 9.0 and incubated with anti-Nek2 antibody (1:100, BD) overnight. The BioGenx polymer kit was used for detection. Positive and negative external controls were stained with the tissue microarray and included the samples used for optimization. Invasive carcinoma cells were scored by an experienced breast pathologist (SJD) using a Leica DM4500B bright field microscope for a visual estimation of percentage of cells showing nuclear Nek2 expression. The degree of Nek2 expression intensity was also scored (S ¼ strong, I ¼ intermediate and W ¼ weak).
Immunoblotting
Cell extracts were prepared in RIPA buffer. Equal amounts of protein were resolved by SDS-polyacrylamide gel electrophoresis and subjected to standard immunoblotting using antibodies recognizing phospho-Rb, total Rb, phospho-histone H3-Ser10 (all from Cell Signaling); total histone H3 (Abcam); or G6PDH (Sigma).
Statistics
Kaplan-Meier survival plots and intergroup comparison statistics were determined using GraphPad PRISM-5 software (GraphPad Software, Inc., La Jolla, CA, USA). The log-rank test was used to evaluate differences in animal survival among experimental groups (P-value). The two-tailed Student's t-test with s.e.m. was used to evaluate differences in all other assays.
